| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | 693.65% | Raymond James | $9 → $5 | Maintains | Outperform |
| 08/08/2023 | 1328.57% | Chardan Capital | $11 → $9 | Maintains | Buy |
| 05/12/2023 | 1328.57% | Raymond James | $10 → $9 | Maintains | Outperform |
| 12/15/2022 | 1646.03% | Chardan Capital | $18 → $11 | Maintains | Buy |
| 11/11/2022 | 1646.03% | Guggenheim | $13 → $11 | Maintains | Buy |
| 11/11/2022 | 693.65% | Citigroup | $7 → $5 | Maintains | Buy |
| 11/08/2022 | 1169.84% | Canaccord Genuity | → $8 | Initiates Coverage On | → Buy |
| 05/17/2022 | 1487.3% | Citigroup | $15 → $10 | Maintains | Buy |
| 05/17/2022 | 1487.3% | Raymond James | $24 → $10 | Maintains | Outperform |
| 03/08/2022 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 03/04/2022 | 3709.52% | Raymond James | $29 → $24 | Maintains | Outperform |
| 01/19/2022 | 852.38% | Goldman Sachs | $29 → $6 | Downgrades | Buy → Neutral |
| 07/01/2021 | 4503.17% | Raymond James | → $29 | Initiates Coverage On | → Outperform |
| 06/15/2021 | 3868.25% | BTIG | → $25 | Initiates Coverage On | → Buy |
| 03/08/2021 | 7042.86% | Chardan Capital | $35.5 → $45 | Maintains | Buy |
| 03/04/2021 | 4661.9% | Goldman Sachs | $28 → $30 | Upgrades | Neutral → Buy |
| 02/04/2021 | 3868.25% | Guggenheim | → $25 | Initiates Coverage On | → Buy |
| 01/04/2021 | 5455.56% | JP Morgan | $25 → $35 | Upgrades | Neutral → Overweight |
| 12/11/2020 | 4344.44% | Citigroup | → $28 | Initiates Coverage On | → Neutral |
| 08/14/2020 | 3868.25% | JP Morgan | → $25 | Downgrades | Overweight → Neutral |
| 06/25/2020 | 4344.44% | Goldman Sachs | → $28 | Downgrades | Buy → Neutral |
| 05/11/2020 | 5058.73% | Chardan Capital | $30 → $32.5 | Maintains | Buy |
| 03/25/2020 | 4661.9% | Chardan Capital | → $30 | Initiates Coverage On | → Buy |
| 03/24/2020 | 4185.71% | Goldman Sachs | → $27 | Initiates Coverage On | → Buy |
What is the target price for Passage Bio (PASG)?
The latest price target for Passage Bio (NASDAQ: PASG) was reported by Raymond James on November 14, 2023. The analyst firm set a price target for $5.00 expecting PASG to rise to within 12 months (a possible 693.65% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Passage Bio (PASG)?
The latest analyst rating for Passage Bio (NASDAQ: PASG) was provided by Raymond James, and Passage Bio maintained their outperform rating.
When is the next analyst rating going to be posted or updated for Passage Bio (PASG)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Passage Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Passage Bio was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
Is the Analyst Rating Passage Bio (PASG) correct?
While ratings are subjective and will change, the latest Passage Bio (PASG) rating was a maintained with a price target of $9.00 to $5.00. The current price Passage Bio (PASG) is trading at is $0.63, which is out of the analyst's predicted range.